Ellagic Acid Enhances RSL3 ‐Induced Ferroptosis by Inhibiting the Nrf2/ HO ‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma
The FASEB Journal · 2026
DOI: 10.1096/fj.202602231r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Jianhua Bai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery. The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Scienc…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Ferroptosis, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Famous Doctor Projects of Yunnan Province, Liu Liang Expert Workstation of Yunnan Province, Yunnan health training project of high level talents.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound therapeutic resistance due to redox adaptation, particularly through Nrf2/HO‐1 pathway activation. Ferroptosis induction via GPX4 inhibitors (e.g., RSL3) is promising but limited by adaptive antioxidant responses. Ellagic acid (EA), a natural polyphenol, may overcome this resistance, yet its role in modulating ferroptosis remains unexplored. In vitro studies used KRAS‐mutant and KRAS wild‐type PDAC cell lines (PANC‐1, BxPC‐3) treated with EA, RSL3, or both. Ferroptosis markers (iron, lipid ROS, MDA, GPX4), viability assays, and pathway analyses (Keap1/Nrf2/HO‐1, p38 MAPK) were evaluated. In vivo, antitumor efficacy was assessed in PANC‐1 xenografts. EA synergized with RSL3, reducing viability in PDAC cells ( p < 0.001) and suppressing tumor growth in vivo ( p < 0.001). Combination therapy amplified ferroptotic markers as increased intracellular iron, MDA, and lipid ROS, versus RSL3 alone, while GPX4 expression decreased. Ferroptosis specificity was confirmed via Fer‐1 rescue. Mechanistically, EA activated p38 MAPK, suppressing Nrf2 nuclear translocation and HO‐1 expression. Keap1 upregulation further enhanced Nrf2 degradation. In vivo, EA + RSL3 downregulated Nrf2/HO‐1 and elevated phospho‐p38 in tumors along with the induction of ferroptosis. EA potentiates RSL3‐induced ferroptosis in PDAC by disrupting the p38/Nrf2/HO‐1 axis and elevating Keap1. This natural compound‐based strategy overcomes redox‐driven resistance, offering a translatable approach for PDAC models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery. The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China.
- Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Pulau Pinang, Malaysia.
- First Clinical Medical College, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
- Department of Biology, Science & Research Institute, Islamic Azad University, Tehran, Iran.
ORCID-Profile: Chern Ein Oon, Yun Jin
Förderung
- Famous Doctor Projects of Yunnan Province
- Liu Liang Expert Workstation of Yunnan Province
- Yunnan health training project of high level talents
Zitieren
APA
Bai, J., Dai, Y., Ein Oon, C., Hu, P., Luo, J., Han, J., Yang, L., Bostani, A., Fei, Z., & Jin, Y. (2026). Ellagic Acid Enhances RSL3 ‐Induced Ferroptosis by Inhibiting the Nrf2/ HO ‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma. The FASEB Journal. https://doi.org/10.1096/fj.202602231r
Vancouver
Bai J, Dai Y, Ein Oon C, Hu P, Luo J, Han J, et al. Ellagic Acid Enhances RSL3 ‐Induced Ferroptosis by Inhibiting the Nrf2/ HO ‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma. The FASEB Journal. 2026. doi:10.1096/fj.202602231r
BibTeX
@article{Bai2026,
author = {Bai, Jianhua and Dai, Yihe and Ein Oon, Chern and Hu, Pingping and Luo, Jia and Han, Jiang and Yang, Liman and Bostani, Amirabas and Fei, Zhenhao and Jin, Yun},
title = {Ellagic Acid Enhances RSL3 ‐Induced Ferroptosis by Inhibiting the Nrf2/ HO ‐1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202602231r}
}
EUVIMED